Baxter International Fourth Quarter 2010 Financial Results Conference Call

DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International (NYSE:BAX) will host a quarterly conference call to discuss its fourth quarter 2010 financial results on Thursday, January 27, 2011, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please dial 866-261-7280 (domestic) or 703-639-1228 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you.

This call is being webcast by Thomson/CCBN and can be accessed at Baxter’s Web site at http://www.baxter.com/. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter’s permission.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.

Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.



CONTACT:

Baxter International Inc.
Investor Relations:
Mary Kay Ladone, +1-847-948-3371
[email protected]
or
Clare Trachtman, +1-847-948-3085
[email protected]

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Devices  Pharmaceutical  General Health

MEDIA:

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.